AKT1 and myelodysplastic syndrome: These data are consistent with a number of previous indications in the literature and follow the extensive work on PI3K/AKT/mTOR in AML, whereas there are not so many new reports on PI3K/AKT/mTOR in MDS progressing on AZA therapy.